Intrahepatic recurrence after surgery in patients with intrahepatic cholangiocarcinoma

Journal of Gastroenterology

Volumn 41, Issue 9, 2006, Pages 925-926

  Yamamoto, Masakazu ^a   Ariizumi, Shun Ichi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BLOOD GROUP LEWIS SYSTEM; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISEASE PREDISPOSITION; EDITORIAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; OBSTRUCTIVE JAUNDICE; PANCREAS DUCT STENOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HEPATECTOMY; HUMANS; INCIDENCE; JAPAN; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 33750143239     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1901-3     Document Type: Editorial

References (22)

1. H Lang GC Sotiropoulos NR Fruhauf M Domland A Paul E Kind et al. 2005 Extended hepatectomy for intrahepatic cholangiocellular carcinoma Ann Surg 241 134-43 15622001
2. Liver Cancer Study Group of Japan. National surveillance of primary liver cancer in Japan, 17th report. Kyoto: Media Planning; 2006 (in Japanese)
3. M Yamamoto K Takasaki T Otsubo H Katsuragawa S Katagiri 2001 Recurrence after surgical resection of intrahepatic cholangiocarcinoma J Hepatobiliary Pancreat Surg 8 154-7 11455472 1:STN:280:DC%2BD3MvgtFSntQ%3D%3D 10.1007/s005340170039
4. SM Weber WR Jarnagin D Klimstra RP DeMatteo Y Fong LH Blumgart 2001 Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes J Am Coll Surg 193 384-91 11584966 1:STN:280:DC%2BD3MrjvVGhuw%3D%3D 10.1016/S1072-7515(01)01016-X
5. T Okabayashi J Yamamoto T Kosuge K Shimada S Yamasaki T Takayama et al. 2001 A new staging system for mass-forming intrahepatic cholangiocarcinoma Cancer 92 2374-83 11745293 1:STN:280:DC%2BD3MnpsF2ntQ%3D%3D 10.1002/ 1097-0142(20011101)92:9<2374::AID-CNCR1585>3.0.CO;2-L
6. M Ohtsuka H Ito F Kimura H Shimizu A Togawa H Yoshidome M Miyazaki 2002 Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival Br J Surg 89 1525-31 12445060 1:STN:280:DC%2BD38noslajsA%3D%3D 10.1046/ j.1365-2168.2002.02268.x
7. N Matsumura M Yamamoto K Takasaki 2002 Usefulness of serum carbohydrate antigen 19-9 in surgical management of mass-forming intrahepatic cholangiocarcinoma (in Japanese with English abstract) Jpn J Gastroenterol Surg 35 130-4
8. S Miwa S Miyagawa A Kobayashi Y Akahane T Nakata M Mihara et al. 2006 Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery J Gastroenterol 41 893-900 10.1007/ s00535-006-1836-8
9. EM Vestergaard HO Hein H Meyer N Grunnet J Jorgensen H Wolf et al. 1999 Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population Clin Chem 45 54-61 9895338 1:CAS:528:DyaK1MXlt1ykuw%3D%3D
10. AH Patel DM Harnois GG Klee NF LaRusso GJ Gores 2000 The utility of CA19-9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis Am J Gastroenterol 95 204-7 10638584 1:STN:280:DC%2BD3c7gt1WhsA%3D%3D 10.1111/j.1572-0241.2000.01685.x
11. XL Qin ZR Wang JS Shi M Lu L Wang QR He 2004 Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA World J Gastroenterol 10 427-32 14760772
12. N Yamanaka E Okamoto T Ando T Oriyama J Fujimoto K Furukawa et al. 1995 Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma Cancer 76 2449-56 8625070 1:STN:280:BymB38zjtVE%3D 10.1002/ 1097-0142(19951215)76:12<2449::AID-CNCR2820761208>3.0.CO;2-V
13. M Yamamoto K Takasaki T Yoshikawa K Ueno M Nakano 1998 Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma? J Surg Oncol 69 162-7 9846503 1:STN:280:DyaK1M%2FmtV2gtQ%3D%3D 10.1002/ (SICI)1096-9098(199811)69:3<162::AID-JSO8>3.0.CO;2-L
14. CG Meyer I Penn L James 2000 Liver transplantation for cholangiocarcinoma: Results in 207 patients Transplantation 69 1633-7 10836374 1:STN:280:DC%2BD3c3psVelsQ%3D%3D 10.1097/ 00007890-200004270-00019
15. R Robles J Figueras VS Turrion C Margarit A Moya E Varo et al. 2004 Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma Ann Surg 239 265-71 14745336 10.1097/ 01.sla.0000108702.45715.81
16. P Ghali PJ Marotta EM Yoshida VG Bain D Marleau K Peltekian et al. 2005 Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canada experience Liver Transpl 11 1412-6 16237695 10.1002/lt.20512
17. DJ Rea JK Heimbach CB Rosen MG Haddock SR Alberts WK Kremers et al. 2005 Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma Ann Surg 242 451-61 16135931
18. SA Khan BR Davidson R Goldin SP Pereira WM Rosenberg SD Taylor-Robinson et al. 2002 Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document Gut 51 Suppl 6 1-9
19. JJ Knox D Hedley A Oza R Feld LL Siu E Chen et al. 2005 Combining gemcitabine in patients with advanced biliary cancer: A phase II trial J Clin Oncol 23 2332-8 15800324 1:CAS:528:DC%2BD2MXjsVyhsr0%3D 10.1200/ JCO.2005.51.008
20. S Thongprasert S Napapan C Charoentum S Moonprakan 2005 Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 16 279-81 15668284 1:STN:280:DC%2BD2M%2FjvFyhsw%3D%3D 10.1093/annonc/mdi046
21. K Hayashi K Uchida M Yamamoto K Yoshitoshi K Takasaki 2005 Two cases of bile duct carcinoma which showed remarkable response to a combination of S-1 plus cisplatium (CDDP) J Appl Res 5 487-91
22. R Higuchi M Yamamoto T Hatori K Shimizu K Imai K Takasaki 2006 Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: Report of a case Surg Today 36 559-62 16715430 10.1007/ s00595-006-3201-1